MedTrace Logo

Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix

NCT00003065 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2014-01-06

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of topotecan and paclitaxel in treating patients who have recurrent or metastatic cancer of the cervix.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

paclitaxel

DRUG

topotecan hydrochloride

Sponsors & Collaborators

  • Herbert Irving Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Amy D. Tiersten, MD · Herbert Irving Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-01-31
Completion
2004-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003065 on ClinicalTrials.gov